

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 15, 2005 Signature: _____

(Jasbir Sagoo, Ph.D.)

Docket No.: 102182-0036
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Matthew During et al.

Confirmation No.: 3969

Application No.: 10/802,497

Art Unit: 1614

Filed: March 16, 2004

Examiner: Not Yet Assigned

For: GLUTAMIC ACID DECARBOXYLASE,
(GAD) BASED DELIVERY SYSTEM

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of each non-patent literature reference is provided on the attached PTO/SB/08A.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56 (b).

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Application No.: 10/802,497

Docket No.: 102182-0036

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 141449, under Order No. 102182-0036.

Dated: March 15, 2005

Respectfully submitted,

By 

Jasbir Sagoo, Ph.D.

Registration No.: 51,177

NUTTER MCCLENNEN & FISH LLP

World Trade Center West

155 Seaport Boulevard

Boston, Massachusetts 02210-2604

(617) 439-2000

(617) 310-9000 (Fax)

Applicant's Attorney

1409812.1



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,497-Conf. #3969
				Filing Date	March 16, 2004
				First Named Inventor	Matthew During
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	102182-0036

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	5,187,162	02/16/1993	Marangos et al.	
	AB	5,681,744	10/28/1997	Greenstein	
	AC	6,682,906	01/27/2004	Tobin et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	WO 95/25805	09/28/1995	PCT		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Bu <i>et al.</i> , "Two Human Glutamate Decarboxylases, 65-kDa GAD and 67-kDa GAD, Are Each Encoded by a Single Gene," <i>Proc. Natl. Acad. Sci. USA</i> , vol. 89, 2115-2119 (March 1992);		
	CB	Cao <i>et al.</i> , "High-Titer, Wild-Type Free Recombinant Adeno-Associated Virus Vector Production Using Intron-Containing Helper Plasmids," <i>Journal of Virology</i> , vol. 74, no. 24, 11456-11463 (December 2000);		
	CC	Celada <i>et al.</i> , "Gabaergic Control of Rat Substantia Nigra Dopaminergic Neurons: Role of Globus Pallidus and Substantia Nigra Pars Reticulata," <i>Neuroscience</i> , vol. 89, no. 3, 813-825 (1999);		
	CD	During <i>et al.</i> , "Peroral Gene Therapy of Lactose Intolerance Using an Adeno-Associated Virus Vector," <i>Nature Medicine</i> , vol 4, no. 10 (October 1998);		
	CE	Kotin, Robert M., "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," <i>Human Gene Therapy</i> , vol. 5, 793-801 (1994);		
	CF	Linderfors, Nils, "Dopaminergic Regulation of Glutamic Acid Decarboxylase mRNA Expression and GABA Release in the Striatum: A Review," <i>Prog. Neuro-Psychopharmacol & Biol. Psychiatry</i> , vol. 17, 887-903 (1993);		
	CG	Martin <i>et al.</i> , "Are GAD ₆₅ and GAD ₆₇ Associated with Specific Pools of GABA in Brain?" <i>Perspectives on Developmental Neurobiology</i> , vol. 5, 119-129 (1998);		
	CH	Miller <i>et al.</i> , "The Central Medial Nucleus: Thalamic Site of Seizure Regulation," <i>Brain Research</i> , vol. 508, 297-300 (1990);		
	CI	Schenk <i>et al.</i> , "Immunization with Amyloid- β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse," <i>Nature</i> , vol. 400, 173-177 (July 1999);		
	CJ	Veliskova <i>et al.</i> , "Subthalamic Nucleus: A New Anticonvulsant Site in the Brain," <i>Neuroreport</i> , vol. 7, no. 11, 1786-1788 (1996); and		
	CK	Xu <i>et al.</i> , "Is the Anticonvulsant Effect of Substantia Nigra Infusion of Gama-Vinyl-GABA (GVG) Mediated by the GABA _A Receptor in Rat Pups?" <i>Developmental Brain Research</i> , vol. 59, 17-21 (1991).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,497-Conf. #3969
				Filing Date	March 16, 2004
				First Named Inventor	Matthew During
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	102182-0036

CL	Robert, JJ et al. "Adenovirus-Mediated Transfer of a Functional GAD Gene Into Nerve Cells: Potential For The Treatment of neurological Diseases" Gene Therapy, Vol. 4, No. 11, pgs. 1237-1245 (1997)	
CM	Mi, Jie et al. "Recombinant Aden-Associated Virus (AAV) Drives Constitutive Production of Glutamate Decarboxylase In Neural Cell Lines" Journal of Neuroscience Research, Vol. 57, pgs. 137-148 (1999);	
CN	New, Kent et al. "Novel Synthesis and Release of GABA In Cerebellar Granule Cell Cultures After Infection With Defective Herpes Simplex Virus Vectors Expressing Glutamic Acid Decarboxylase" Molecular Brain Research, Vol., pgs. 121-135 (1998);	
CO	Navarro, V. et al. "Efficient Gene Transfer and Long-Term Expression In Neurons Using A Recombinant Adenovirus With A neuron-Specific Promoter" Gene Therapy, Vol. 6, pgs. 1884-1892 (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/802,497

Attorney Docket No.: 102182-0036

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on March 15, 2005
Date


Signature

Jasbir Sagoo, Ph.D.

Typed or printed name of person signing Certificate

51,177
Registration Number, if applicable

617-439-2000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (w/15 references attached)
Return Postcard